DE212014000063U1 - Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung - Google Patents
Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung Download PDFInfo
- Publication number
- DE212014000063U1 DE212014000063U1 DE212014000063.7U DE212014000063U DE212014000063U1 DE 212014000063 U1 DE212014000063 U1 DE 212014000063U1 DE 212014000063 U DE212014000063 U DE 212014000063U DE 212014000063 U1 DE212014000063 U1 DE 212014000063U1
- Authority
- DE
- Germany
- Prior art keywords
- alzheimer
- disease
- dementia
- cognitive impairment
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 70
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 56
- 206010012289 Dementia Diseases 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title claims abstract description 43
- 150000001558 benzoic acid derivatives Chemical class 0.000 title claims abstract description 14
- 230000002265 prevention Effects 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 95
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 48
- 235000010234 sodium benzoate Nutrition 0.000 claims description 45
- 239000004299 sodium benzoate Substances 0.000 claims description 45
- 235000010237 calcium benzoate Nutrition 0.000 claims description 2
- 239000004301 calcium benzoate Substances 0.000 claims description 2
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 235000010235 potassium benzoate Nutrition 0.000 claims description 2
- 239000004300 potassium benzoate Substances 0.000 claims description 2
- 229940103091 potassium benzoate Drugs 0.000 claims description 2
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 40
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 40
- 230000000694 effects Effects 0.000 description 35
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 33
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 29
- 239000000902 placebo Substances 0.000 description 27
- 229940068196 placebo Drugs 0.000 description 27
- 239000003814 drug Substances 0.000 description 26
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 22
- 229930195711 D-Serine Natural products 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 15
- 230000032683 aging Effects 0.000 description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 15
- 230000015654 memory Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- PMHDSACGRKBACK-UHFFFAOYSA-N 4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1C=C(C(=O)O)N2 PMHDSACGRKBACK-UHFFFAOYSA-N 0.000 description 10
- 229940121734 D-amino-acid oxidase inhibitor Drugs 0.000 description 10
- 229940050390 benzoate Drugs 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000001149 cognitive effect Effects 0.000 description 10
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000001755 vocal effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000013016 learning Effects 0.000 description 9
- 230000003936 working memory Effects 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 8
- 239000000544 cholinesterase inhibitor Substances 0.000 description 8
- 229930195712 glutamate Natural products 0.000 description 8
- 201000000980 schizophrenia Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000001178 neural stem cell Anatomy 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 210000004129 prosencephalon Anatomy 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000019771 cognition Effects 0.000 description 6
- 230000006999 cognitive decline Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000008520 organization Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 5
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 5
- 238000000585 Mann–Whitney U test Methods 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 5
- 229960003530 donepezil Drugs 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 230000007310 pathophysiology Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000005062 synaptic transmission Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000018899 Glutamate Receptors Human genes 0.000 description 4
- 108010027915 Glutamate Receptors Proteins 0.000 description 4
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 102100035717 Serine racemase Human genes 0.000 description 4
- 108010006152 Serine racemase Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940005524 anti-dementia drug Drugs 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 4
- 229960004640 memantine Drugs 0.000 description 4
- 230000009223 neuronal apoptosis Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 229960003980 galantamine Drugs 0.000 description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004031 neuronal differentiation Effects 0.000 description 3
- 230000007996 neuronal plasticity Effects 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 229960004526 piracetam Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- -1 sodium benzoate Chemical class 0.000 description 3
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 101100313653 Caenorhabditis elegans kat-1 gene Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 description 2
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 2
- 102100021209 Kynurenine-oxoglutarate transaminase 1 Human genes 0.000 description 2
- 101710165103 Kynurenine-oxoglutarate transaminase 1 Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000014107 chromosome localization Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000002475 cognitive enhancer Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 230000006998 cognitive state Effects 0.000 description 2
- 208000030251 communication disease Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- 229950004794 dizocilpine Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000020796 long term synaptic depression Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000007334 memory performance Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 230000006977 prepulse inhibition Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 229940006198 sodium phenylacetate Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007979 neuropsychological functioning Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000026797 positive regulation of anti-apoptosis Effects 0.000 description 1
- 230000015284 positive regulation of neurogenesis Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000003414 procognitive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG2014/000140 WO2015147742A1 (fr) | 2014-03-24 | 2014-03-24 | Utilisation d'un sel d'acide benzoïque dans la fabrication d'une composition pour prévenir ou traiter la démence ou un trouble cognitif léger |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE212014000063U1 true DE212014000063U1 (de) | 2015-10-12 |
Family
ID=54196083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE212014000063.7U Expired - Lifetime DE212014000063U1 (de) | 2014-03-24 | 2014-03-24 | Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2016517866A (fr) |
| KR (2) | KR20160029837A (fr) |
| AU (1) | AU2014386718B8 (fr) |
| CA (1) | CA2902498C (fr) |
| DE (1) | DE212014000063U1 (fr) |
| SG (1) | SG11201507188QA (fr) |
| WO (1) | WO2015147742A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3468946A4 (fr) | 2016-06-13 | 2020-02-12 | Syneurx International (Taiwan) Corp. | Co-cristaux de benzoate de lithium et leurs utilisations |
| CA3027297A1 (fr) * | 2016-06-13 | 2017-12-21 | Syneurx International (Taiwan) Corp. | Co-cristaux de benzoate de sodium et leurs utilisations |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| WO2018160055A1 (fr) * | 2017-03-03 | 2018-09-07 | Excelsior Pharmatech Labs | Procédé de prévention ou de traitement de troubles du spectre de l'autisme par sel d'acide benzoïque |
| JP7034314B2 (ja) * | 2017-11-22 | 2022-03-11 | 潔欣 林 | うつ病を予防または治療するための安息香酸またはその塩および誘導体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| CN1922157B (zh) * | 2003-12-29 | 2011-01-12 | 塞普拉科公司 | 苯并[d]异噁唑-3-醇DAAO抑制剂 |
| BRPI1007173A2 (pt) * | 2009-01-20 | 2016-02-23 | Los Angeles Biomed Res Inst | composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico |
| GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| PE20141361A1 (es) * | 2011-11-15 | 2014-10-13 | Takeda Pharmaceutical | Compuesto heterociclico dihidroxi aromatico |
-
2014
- 2014-03-24 KR KR1020167003184A patent/KR20160029837A/ko not_active Application Discontinuation
- 2014-03-24 SG SG11201507188QA patent/SG11201507188QA/en unknown
- 2014-03-24 AU AU2014386718A patent/AU2014386718B8/en active Active
- 2014-03-24 WO PCT/SG2014/000140 patent/WO2015147742A1/fr active Application Filing
- 2014-03-24 CA CA2902498A patent/CA2902498C/fr active Active
- 2014-03-24 JP JP2016510654A patent/JP2016517866A/ja active Pending
- 2014-03-24 KR KR1020177024853A patent/KR102162073B1/ko active IP Right Grant
- 2014-03-24 DE DE212014000063.7U patent/DE212014000063U1/de not_active Expired - Lifetime
Non-Patent Citations (81)
| Title |
|---|
| Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, et al. (2008): In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol. 18: 200-214 |
| Albert M, Blacker D, Moss MB, Tanzi R, McArdle JJ (2007): Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology. 21: 158-169 |
| Batshaw ML, Hyman SL, Coyle JT, Robinson MB, Qureshi IA, Mellits ED, et al. (1988): Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse. Pediatric research. 23: 368-374 |
| Birks J (2006): Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. CD005593 |
| Birks J, Flicker L (2006): Donepezil for mild cognitive impairment. Cochrane Database Syst Rev.CD006104 |
| Birks J, Grimley Evans J (2009): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. CD003120 |
| Budd D, Burns LC, Guo Z, L'Italien G, Lapuerta P (2011): Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation. ClinicoEconomics and outcomes research: CEOR. 3: 189-195 |
| Burns A, O'Brien J, Auriacombe S, Ballard C, Broich K, Bullock R, et al. (2006): Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 20: 732-755 |
| Carlesimo GA, Mauri M, Graceffa AM, Fadda L, Loasses A, Lorusso S, et al. (1998): Memory performances in young, elderly, and very old healthy individuals versus patients with Alzheimer's disease: evidence for discontinuity between normal and pathological aging. Journal of clinical and experimental neuropsychology. 20: 14-29 |
| Chef P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M (2001): Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry. 58: 853-858 |
| Chessell IP, Procter AW, Francis PT, Bowen DM (1991): D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res. 565: 345-348 |
| China Medical University Hospital, Taiwan (CMU 101-AWARD-13, DMR-99-153) |
| Choi DW (1992): Excitotoxic cell death. Journal of neurobiology. 23: 1261-1276 |
| Cunningham JB M-GE (2007): Power, effect and sample size using of GPower: practical issues for researchers and members of research ethics committees. Evidence Based Midwifery 5: 132-136 |
| Espinosa A, Alegret M, Valero S, Vinyes-Junque G, Hernandez I, Mauleon A, et al. (2013): A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis. 34: 769-780 |
| Esposito S, Pristera A, Maresca G, Cavallaro S, Felsani A, Florenzano F, et al. (2012): Contribution of serine racemase/d-serine pathway to neuronal apoptosis. Aging Cell 11: 588-598 |
| Farina N, Isaac MG, Clark AR, Rusted J, Tabet N (2012): Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev. 11:CD002854 |
| Fellgiebel A (2007): [Alzheimer - Medikamente bei Mild Cognitive Impairment]. Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenärzte und Psychiater. 21: 230-233 |
| Flicker L, Grimley Evans G (2001): Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. CD001011 |
| Folstein MF, Folstein SE, McHugh PR (1975): "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 12: 189-198 |
| Fukui K, Miyake Y (1992): Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. The Journal of biological chemistry. 267: 18631-18638 |
| Gardoni F, Mauceri D, Malinverno M, Polli F, Costa C, Tozzi A, et al. (2009): Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but no long-term depression. J Neurosci. 29: 669-677 |
| Gong N, Gao ZY, Wang YC, Li XY, Huang JL, Hashimoto K, et al. (2011): A series of D-amino acid oxidase inhibitors specifically prevents and reverses formalin-induced tonic pain in rats. The Journal of pharmacology and experimental therapeutics. 336: 282-293 |
| Habekost T, Vogel A, Rostrup E, Bundesen C, Kyllingsbaek S, Garde E, et al. (2013): Visual processing speed in old age. Scandinavian journal ofpsychology. 54: 89-94 |
| Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, et al. (2009): Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 65: 1103-1106 |
| Hashimoto K, Fukushima T, Shimizu E, Okada S, Komatsu N, Okamura N, et al. (2004): Possible role of D-serine in the pathophysiology of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 28: 385-388 |
| http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/expert-blog/dementia-definitions/bgp-20055922 |
| Huang X, Kong H, Tang M, Lu M, Ding JH, Hu G (2012): D-Serine regulates proliferation and neuronal differentiation of neural stem cells from postnatal mouse forebrain. CNS Neurosci Ther. 18: 4-13 |
| Huang YJ, Lin CH, Lane HY, Tsai GE (2012): NMDA Neurotransmission Dysfunktion in Behavioral and Psychological Symptoms of Alzheimer's Disease. Current neuropharmacology. 10: 272-285 |
| Kalia LV, Kalia SK, Salter MW (2008): NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 7: 742-755 |
| Kapoor R, Lim KS, Cheng A, Garrick T, Kapoor V (2006): Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 1106: 205-210 |
| Lai CH, Lane HY, Tsai GE (2012): Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naive patient with major depression. Biol Psychiatry. 71: e9-e10 |
| Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chef PW, et al. (2013): A Randomized, Double-Blind, Placebo-Controlled Add-on Treatment of Benzoate, a D-Amino Acid Oxidase Inhibitor, for Schizophrenia. JAMA Psychiatry 70: 1267-1275 |
| Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987): The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta psychiatrica Scandinavica Supplementum. 334: 1-100 |
| Lipton SA, Rosenberg PA (1994): Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 330: 613-622 |
| Loy C, Schneider L (2006): Galantamine for Alzheimer's disease and mild cognitve impairment. Cochrane Database Syst Rev.CD001747 |
| Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL (2009): Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology. 72: 2115-2121 |
| Malouf R, Grimley Evans J (2008): Folic acid with oder without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. CD004514 |
| Mattson MP (2008): Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 1144: 97-112 |
| McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984): Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34: 939-944 |
| Morris JC (1993): The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 43: 2412-2414 |
| National Science Council, Taiwan (NSC 99-3114-B-182A-003, NSC 101-2314-B-182A-073-MY2 und NSC-101-2325-B-039-009) |
| O'Brien JT, Burns A (2011): Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 25: 997-1019 |
| Olney JW, Farber NB (1995): Glutamate receptor dysfunktion and schizophrenia. Arch Gen Psychiatry. 52: 998-1007 |
| Pallas M, Camins A (2006): Molecular and Biochemical Features in Alzheimer disease. Curr Pharm Des. 12: 4389-4408 |
| Park HK, Shishido Y, Ichise-Shishido S, Kawazoe T, Ono K, Iwana S, et al. (2006): Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity. Journal of biochemistry. 139: 295-304 |
| Perneczky R, Pohl C, Sorg C, Hartmann J, Komossa K, Alexopoulos P, et al. (2006): Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age and ageing. 35: 240-245 |
| Price SE, Kinsella GJ, Ong B, Storey F, Mullaly F, Phillips M, et al. (2012): Semantic verbal fluency strategies in amnestic mild cognitive impairment. Neuropsychology. 26: 490-497 |
| Procter AW, Stirling JM, Stratmann GC, Cross AJ, Bowen DM (1989): Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease. Neurosci Lett. 101: 62-66 |
| Procter AW, Wong EH, Stratmann GC, Lowe SL, Bowen DM (1989): Reduced glycine stimulation of [3H]MK-801 binding in Alzheimers disease. J Neurochem. 53: 698-704 |
| Raschetti R, Albanese E, Vanacore N, Maggini M (2007): Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS medicine. 4: e338 |
| Reisberg B, Doody R, Stöffler B, Schmitt F, Ferris S, Möbius HJ (2003): Memantine in Moderate-to-Severe Alzheimer Disease. N Engl J Med. 348: 1333-1341 |
| Riederer P, Hoyer S (2006): From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm. 113: 1671-1677 |
| Rios C, Pascual LF, Santos S, Lopez F, Fernandez T, Navas I, et al. (2001): [Arbeitsgedächtnis und komplexe Aktivitäten des täglichen Lebens in den Anfangsstadien von Alzheimer-Krankheit]. Revista de neurologia. 33: 719-722 |
| Rosen WG, Mohs RC, Davis KL (1984): A new rating scale for Alzheimer's disease. Am J Psychiatry. 141: 1356-1364 |
| Rosenthal R RR (1991): Essentials of behavioral research: Methods and data analysis. 2. Ausg. New York: McGraw Hill |
| Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA (2005): Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology. 30: 633-639 |
| Russ TC, Morling JR (2012): Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 9:CD009132 |
| Salmon DP (2012): Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Current topics in behavioral neurosciences. 10: 187-212 |
| Salthouse TA (1996): The processing-speed theory of adult age differences in cognition. Psychological review. 103: 403-428 |
| Sasabe J, Miyoshi Y, Suzuki M, Mita M, Konno R, Matsuoka M, et al. (2012): D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci USA. 109: 627-632 |
| Scarpini E, Scheltens P, Feldman H (2003): Treatment of Alzheimer'disease: current status and new perspectives. Lancet neurology. 2: 539-547 |
| Schneider LS, Dagerman KS, Higgins JP, McShane R (2011): Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 68: 991-998 |
| Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. (1997): Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 11 Suppl 2: 522-32 |
| Segovia G, Porras A, Del Arco A, Mora F (2001): Glutamatergic neurotransmission in aging: a critical perspective. Mech Ageing Dev. 122: 1-29 |
| Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski F, Crane PK, et al. (2012): The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain imaging and behavior. 6: 489-501 |
| Smith SM, Uslaner JM, Hutson PH (2010): The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. The open medicinal chemistry journal. 4: 3-9 |
| Smith SM, Uslaner JM, Yao L, Mullins CM, Surles NO, Huszar SL, et al. (2009): The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. The Journal of pharmacology and experimental therapeutics. 328: 921-930 |
| Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. (2011): Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute of Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 7: 280-292 |
| Strick CA, Li C, Scott L, Harvey B, Hajos M, Steyn Si, et al. (2011): Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Neuropharmacology. 61: 1001-1015 |
| Sydenham F, Dangour AD, Lim WS (2012): Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 6:CD005379 |
| Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) |
| Tilleux S, Hermans E (2007): Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 85: 2059-2070 |
| Tsai GE, Falk WE, Gunther J, Coyle JT (1999): Improved cognition in Alzheimers disease with short-term D-cycloserine treatment. Am J Psychiatry. 156: 467-469 |
| Vanoni MA, Cosma A, Mazzeo D, Mattevi A, Todone F, Curti B (1997): Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase. Biochemistry. 36: 5624-5632 |
| Verrall L, Walker M, Rawlings N, Benzel I, Kew JN, Harrison PJ, et al. (2007): d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. The European journal of neuroscience. 26: 1657-1669 |
| Wechsler D (1997): Wechsler Memory Scale, 3. Ausg. Psychological Association, San Antonio, TX: Psychological Association |
| WHO-Concise International Chemical Assessment Dokument Nr. 26. WHO G, 2000 http://www.inchem.org/documents/cicads/cicads/cicad26.htm |
| World Health Organization (2000): Concise International Chemical Assessment. Dokument Nr. 26. Genf: World Health Organization. Erhältlich bei: http://www.who.int/ipcs/publications/cicad/cicad26_rev_1.pdf |
| Yoon WJ, Won SJ, Ryu BR, Gwag BJ (2003): Blockade of ionichtropic glutamate receptors produces neuronal apoptosis through the Bax-cytochrome C-caspase pathway: the causative role von Ca2+ deficiency. J Neurochem. 85: 525-533 |
| Zhao WJ, Gao ZY, Wei H, Nie HZ, Zhao Q, Zhou XJ, et al. (2010): Spinal D-amino acid oxidase contributes to neuropathic pain in rats. The Journal of pharmacology and experimental therapeutics. 332: 248-254 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160029837A (ko) | 2016-03-15 |
| AU2014386718B8 (en) | 2017-12-07 |
| WO2015147742A1 (fr) | 2015-10-01 |
| AU2014386718A1 (en) | 2015-10-08 |
| KR20170104658A (ko) | 2017-09-15 |
| CA2902498A1 (fr) | 2015-09-24 |
| AU2014386718A8 (en) | 2017-12-07 |
| CA2902498C (fr) | 2017-03-28 |
| CA2902498F (fr) | 2015-09-24 |
| JP2016517866A (ja) | 2016-06-20 |
| SG11201507188QA (en) | 2015-10-29 |
| AU2014386718B2 (en) | 2017-07-20 |
| KR102162073B1 (ko) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial | |
| DE212014000063U1 (de) | Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung | |
| Piccinin et al. | Neuropsychological effects of L-deprenyl in Alzheimer's type dementia | |
| AU2012331689B2 (en) | Improving recognition | |
| DK2029130T3 (en) | ALFA -aminoamide DERIVATIVES THAT ARE APPLICABLE IN TREATMENT OF LEARNING DISORDERS | |
| Ghika et al. | Idazoxan treatment in progressive supranuclear palsy | |
| Moretti et al. | Depression and Alzheimer's disease: symptom or comorbidity? | |
| Growdon et al. | Piracetam combined with lecithin in the treatment of Alzheimer's disease | |
| Fleming et al. | An intermittent, controlled-rate, slow progressive degeneration model of Parkinson’s disease: antiparkinson effects of Sinemet and protective effects of methylphenidate | |
| US20130295179A1 (en) | Novel omega-3 and omega-6 fatty acid compositions and uses thereof | |
| Rickels et al. | A placebo‐controlled, double‐blind, clinical trial of paroxetine in depressed outpatients | |
| Bruce‐Jones et al. | Indomethacin and cognitive function in healthy elderly volunteers. | |
| Bhattacharya et al. | Attention enhancing effects of methylphenidate are age-dependent | |
| JP6550426B2 (ja) | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 | |
| TWI573588B (zh) | 苯甲酸鹽用於製備治療失智症或輕度認知障礙之醫藥組成物的用途 | |
| Voronkova et al. | Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia | |
| CA3054869A1 (fr) | Compositions et procedes qui attenuent le vieillissement cognitif chez des individus qui ne presentent pas de demence | |
| Klawans et al. | L-dopa in Parkinsonism associated with cerebellar dysfunction (probable olivopontocerebellar degeneration) | |
| Öhman | Effect of exercise on cognition, physical functioning, fall rate, and neuropsychiatric symptoms in people with dementia | |
| Luijpen et al. | Effects of transcutaneous electrical nerve stimulation (TENS) on memory in elderly with mild cognitive impairment | |
| Tanaka et al. | Pharmacotherapy of aphasia | |
| EP3388061A1 (fr) | Acides gras omega 3, composes liberant no, vitamine b12 et choline comme neuroprotecteurs pour patients sans demence | |
| Yokel | Aluminum exposure produces learning and memory deficits: A model of Alzheimer’s disease | |
| TWEEDY et al. | Lecithin treatment of cognitively impaired Parkinson's patients | |
| US20170216234A1 (en) | Benzoates for use in treating dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification | ||
| R082 | Change of representative |
Representative=s name: GMP PATENTANWALTSGESELLSCHAFT UND RECHTSANWALT, DE Representative=s name: GOTTSCHALK MAIWALD PATENTANWALTS- UND RECHTSAN, DE Representative=s name: GOTTSCHALK MAIWALD PATENTANWALTSGESELLSCHAFT U, DE |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years | ||
| R151 | Utility model maintained after payment of second maintenance fee after six years | ||
| R152 | Utility model maintained after payment of third maintenance fee after eight years | ||
| R071 | Expiry of right |